[Treatment with human recombinant erythropoietin and frequency of retinopathy of prematurity].
The aim of our study was to assess frequency of ROP in VLBW and ELBW treated with rhEPO in preventing anemia. In 36 newborns with birth weight 480 to 1490 g (median 1032 g) and 24 to 32 weeks of gestational age (median 28.0 weeks) we have estimated concentration of cord erythropoietin. According this concentration we have divided our material into two groups. In first group of 22 newborns with cord concentration of EPO < 10 mU/ml we started early erythropoietin (rhEPO) therapy which was continued by 6 weeks. Second group of 14 no early usage newborns had cord EPO concentration > 10 mU/ml. In second group the control level of serum EPO was measured in 15th day of life. In newborns from second group in which the EPO concentration during two weeks decreased below 10 mU/ml we started to use rhEPO as a late usage. First oculistic consultation took place in the 5th week of life according to the screening performed in our country. In the first group (n = 22) with early EPO treatment retinopathy was recognized in 15 preterm newborns (68.2%). Eight of them (53.3%) had advanced form of retinopathy ROP (III lub III+) and were undergone a laserotherapy. In the group of late usage of rhEPO (n = 14) 8 newborns (57.1%) had signs of retinopathy, but only 3 of them (37.5%) required laserotherapy because of advanced form of ROP (III lub III+).
Rudzińska
Iwona M
IM
II Katedra i Klinika Połoznictwa i Ginekologii Akademii Medycznej w Warszawie.
Kornacka
Maria K
MK
Pawluch
Robert
R
D003131:Combined Modality Therapy; D004921:Erythropoietin / Q000627:therapeutic use*; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D019102:Infant, Very Low Birth Weight; D053685:Laser Therapy; D011994:Recombinant Proteins; D012178:Retinopathy of Prematurity / Q000188:drug therapy* / Q000601:surgery; D012189:Retrospective Studies
D011994:Recombinant Proteins; D004921:Erythropoietin